Seelos Therapeutics Stock Probability of Future OTC Stock Price Finishing Over 0.3705
| SEEL Stock | USD 0.39 0.11 22.00% |
Seelos |
Seelos Therapeutics Target Price Odds to finish over 0.3705
The tendency of Seelos OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 0.37 in 90 days |
| 0.39 | 90 days | 0.37 | about 92.39 |
Based on a normal probability distribution, the odds of Seelos Therapeutics to stay above $ 0.37 in 90 days from now is about 92.39 (This Seelos Therapeutics probability density function shows the probability of Seelos OTC Stock to fall within a particular range of prices over 90 days) . Probability of Seelos Therapeutics price to stay between $ 0.37 and its current price of $0.39 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Seelos Therapeutics has a beta of -4.28. This usually implies as returns on its benchmark rise, returns on holding Seelos Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Seelos Therapeutics is expected to outperform its benchmark. Additionally Seelos Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Seelos Therapeutics Price Density |
| Price |
Predictive Modules for Seelos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Seelos Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Seelos Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Seelos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Seelos Therapeutics is not an exception. The market had few large corrections towards the Seelos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Seelos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Seelos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -3.06 | |
β | Beta against Dow Jones | -4.28 | |
σ | Overall volatility | 1.69 | |
Ir | Information ratio | -0.26 |
Seelos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Seelos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Seelos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Seelos Therapeutics is not yet fully synchronised with the market data | |
| Seelos Therapeutics generated a negative expected return over the last 90 days | |
| Seelos Therapeutics has high historical volatility and very poor performance | |
| Seelos Therapeutics has some characteristics of a very speculative penny stock | |
| Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
| Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Latest headline from gurufocus.com: Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer |
Seelos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Seelos OTC Stock often depends not only on the future outlook of the current and potential Seelos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Seelos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.9 M | |
| Cash And Short Term Investments | 3 M |
Seelos Therapeutics Technical Analysis
Seelos Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Seelos OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Seelos Therapeutics. In general, you should focus on analyzing Seelos OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Seelos Therapeutics Predictive Forecast Models
Seelos Therapeutics' time-series forecasting models is one of many Seelos Therapeutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Seelos Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Seelos Therapeutics
Checking the ongoing alerts about Seelos Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Seelos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Seelos Therapeutics is not yet fully synchronised with the market data | |
| Seelos Therapeutics generated a negative expected return over the last 90 days | |
| Seelos Therapeutics has high historical volatility and very poor performance | |
| Seelos Therapeutics has some characteristics of a very speculative penny stock | |
| Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
| Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Latest headline from gurufocus.com: Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer |
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.